Biperiden administration in normal sleep and after rapid eye movement sleep deprivation in healthy volunteers.
Twenty-six healthy volunteers were randomly assigned to one of four groups. Groups Bip-4 and Bip-6, each with six subjects, received 4 and 6 mg of biperiden, respectively, and were studied on acclimatization, baseline, biperiden, and follow-up nights. Group REM-P (n = 7) and Group REM-Bip (n = 7) were studied on acclimatization, baseline, six nights of REM sleep deprivation, and one recovery (treatment) night with either placebo (group REM-P) or biperiden (group REM-Bip), and one follow-up night. Biperiden 4 and 6 mg increased REM sleep latency and biperiden 6 mg reduced REM sleep time. On the recovery night following REM sleep deprivation Group REM-P and REM-Bip showed an increase in sleep continuity. REM sleep time in the REM-P group was increased during the recovery (treatment) night (REM sleep recovery), while the REM-Bip group did not show a significant REM sleep increase during recovery (treatment) night. It was not until the follow-up night that REM sleep increased in the REM-Bip group.
Salin-Pascual
R J
RJ
Psychobiology Department, Mexican Institute of Psychiatry.
Granados-Fuentes
D
D
Galicia-Polo
L
L
Nieves
E
E
Echeverry
J
J
D000328:Adult; D000704:Analysis of Variance; D001712:Biperiden / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D011976:Receptors, Muscarinic / Q000187:drug effects / Q000502:physiology; D012016:Reference Values; D012892:Sleep Deprivation / Q000502:physiology*; D012895:Sleep, REM / Q000187:drug effects*
D011976:Receptors, Muscarinic; D001712:Biperiden